These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 24809125)

  • 1. Early Alzheimer's indicator?
    Johns Hopkins Med Lett Health After 50; 2014 Jan; 25(13):6. PubMed ID: 24809125
    [No Abstract]   [Full Text] [Related]  

  • 2. Biomarkers for the early diagnosis of Alzheimer's disease.
    de Leon MJ; Klunk W
    Lancet Neurol; 2006 Mar; 5(3):198-9. PubMed ID: 16488371
    [No Abstract]   [Full Text] [Related]  

  • 3. Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF study.
    Buerger K; Ewers M; Andreasen N; Zinkowski R; Ishiguro K; Vanmechelen E; Teipel SJ; Graz C; Blennow K; Hampel H
    Neurology; 2005 Nov; 65(9):1502-3. PubMed ID: 16275849
    [No Abstract]   [Full Text] [Related]  

  • 4. Advances on biological markers in early diagnosis of Alzheimer disease.
    Padovani A; Borroni B; Di Luca M
    Adv Clin Chem; 2005; 39():107-29. PubMed ID: 16013669
    [No Abstract]   [Full Text] [Related]  

  • 5. The diagnosis of Alzheimer disease before it is Alzheimer dementia.
    Frisoni GB; Padovani A; Wahlund LO
    Arch Neurol; 2003 Jul; 60(7):1023; author reply 1023-4. PubMed ID: 12873864
    [No Abstract]   [Full Text] [Related]  

  • 6. Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease.
    Schmand B; Huizenga HM; van Gool WA
    Psychol Med; 2010 Jan; 40(1):135-45. PubMed ID: 19863841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF APPs alpha and phosphorylated tau protein levels in mild cognitive impairment and dementia of Alzheimer's type.
    Fellgiebel A; Kojro E; Müller MJ; Scheurich A; Schmidt LG; Fahrenholz F
    J Geriatr Psychiatry Neurol; 2009 Mar; 22(1):3-9. PubMed ID: 19073834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid TAU protein and amyloid beta42 in mild cognitive impairment: prediction of progression to Alzheimer's disease and correlation with the neuropsychological examination.
    Ivanoiu A; Sindic CJ
    Neurocase; 2005 Feb; 11(1):32-9. PubMed ID: 15804922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI.
    Nordlund A; Rolstad S; Klang O; Lind K; Pedersen M; Blennow K; Edman A; Hansen S; Wallin A
    J Int Neuropsychol Soc; 2008 Jul; 14(4):582-90. PubMed ID: 18577287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Neurochemical early and differential diagnostics for Alzheimer's disease].
    Wiltfang J; Lewczuk P; Maler M; Bleich S; Smirnov A; Kornhuber J
    MMW Fortschr Med; 2004 Sep; 146(38):38-40. PubMed ID: 15532429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [MCI-plus: mild cognitive impairment with rapid progression. Part II: Biomarkers and research methods].
    Förstl H; Werheid K; Ulm K; Schönknecht P; Schmidt R; Pantel J; Hörr R; Gutzmann H; Gertz HJ; Frölich L; Bickel H
    Dtsch Med Wochenschr; 2009 Jan; 134(3):88-91. PubMed ID: 19142839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sharpen that needle.
    Herskovits AZ; Growdon JH
    Arch Neurol; 2010 Aug; 67(8):918-20. PubMed ID: 20697041
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease.
    Smach MA; Charfeddine B; Ben Othman L; Lammouchi T; Dridi H; Nafati S; Ltaief A; Bennamou S; Limem K
    Eur Neurol; 2009; 62(6):349-55. PubMed ID: 19786779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The diagnostic value of tau protein, beta-amyloid (1-42) and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimer's disease in the early stages.
    Kapaki E; Liappas I; Paraskevas GP; Theotoka I; Rabavilas A
    Int J Geriatr Psychiatry; 2005 Aug; 20(8):722-9. PubMed ID: 16035118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [CSF levels of total tau protein in patients with mild cognitive impairment and Alzheimer's disease].
    Kaiser E; Schönknecht P; Hunt A; Thomann PA; Pantel J; Schröder J
    Z Gerontol Geriatr; 2008 Dec; 41(6):497-501. PubMed ID: 18327693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body mass index is associated with biological CSF markers of core brain pathology in Alzheimer's disease.
    Jawaid A; Leske H; Neumann M
    Neurobiol Aging; 2012 Jul; 33(7):e1-2. PubMed ID: 22244089
    [No Abstract]   [Full Text] [Related]  

  • 17. New research criteria for the diagnosis of Alzheimer's disease applied in a memory clinic population.
    Bouwman FH; Verwey NA; Klein M; Kok A; Blankenstein MA; Sluimer JD; Barkhof F; van der Flier WM; Scheltens P
    Dement Geriatr Cogn Disord; 2010; 30(1):1-7. PubMed ID: 20606438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biomarkers in cerebrospinal fluid and blood in memory complaints].
    Zetterberg H; Andreasen N; Blennow K
    Lakartidningen; 2009 May 13-19; 106(20):1386-9. PubMed ID: 19585836
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of plasma Abeta40 and Abeta42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.
    Kester MI; Verwey NA; van Elk EJ; Scheltens P; Blankenstein MA
    Neurobiol Aging; 2010 Apr; 31(4):539-40; author reply 541. PubMed ID: 18963255
    [No Abstract]   [Full Text] [Related]  

  • 20. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
    van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM
    Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.